Moleculin Biotech
MBRX
23 hedge funds and large institutions have $4.32M invested in Moleculin Biotech in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 22 → 23 (+1)
0.08% more ownership
Funds ownership: 10.34% → 10.42% (+0.08%)
18% less capital invested
Capital invested by funds: $5.26M → $4.32M (-$943K)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$43.6K |
| 2 |
JE
JMAC Enterprises
Newtown,
Pennsylvania
|
+$20.4K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$17.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.33K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$19.8K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$19K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$6.4K |
| 4 |
SCM
Sio Capital Management
New York
|
-$5.82K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$5.82K |
MBRX Hedge Fund Activity: Q2 2022 in Review
23 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2022, worth a combined $4.32M — down 18% from $5.26M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MBRX positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $43.6K. The largest seller was Two Sigma Advisers, cutting an estimated $19.8K.
- 23 institutional investors held Moleculin Biotech (MBRX) as of Q2 2022, up from 22 in Q1 2022.
- Funds reported $4.32M of Moleculin Biotech stock for Q2 2022, down 18% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q2 2022 and 2 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q2 2022 was Renaissance Technologies, an estimated $43.6K added.
- The largest Moleculin Biotech seller in Q2 2022 was Two Sigma Advisers, an estimated $19.8K sold.
Based on aggregated 13F filings for Q2 2022.